We are delighted to inform you that due to the positive customer response, the molecular diagnostic products of our partner AmoyDx® are now available to our customers in Switzerland through ZytoMax Schweiz GmbH, a sister company of Zytomed Systems GmbH.
AmoyDx® is a research and development-based diagnostics company with over 1000 employees that focuses on molecular diagnostics for oncological precision medicine. The primarily CE/IVD labeled qPCR and NGS products have proven to be of excellent quality and reliability, as confirmed by numerous successful external proficiency tests conducted by our customers. Furthermore, our product and laboratory team are happy to offer advice and active support during the introduction and establishment of the products.
If you are interested, please do not hesitate to contact your local contact at ZytoMax Schweiz GmbH, via e-mail at info@zytomax.ch or phone at +41 79 965 68 67.
Breast cancer is one of the most common cancers in women worldwide. In Germany, every 8th woman is diagnosed with breast cancer. Until now, therapies have been based on the presence/absence of (hormone) receptors or the Her2 receptor in metastatic/non-metastatic breast cancer.
Today, we are proud to announce that ZytoVision, our sister company, received the IVDR certification!